Ensign Peak Advisors
PTGX icon

Ensign Peak Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Ensign Peak Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Sell
3,786
-700
-16% -$73.1K ﹤0.01% 1012
2026
Q1 		$473K Hold
4,486
– – ﹤0.01% 978
2025
Q4 		$392K Sell
4,486
-6,500
-59% -$532K ﹤0.01% 1018
2025
Q3 		$730K Sell
10,986
-12,150
-53% -$691K ﹤0.01% 1201
2025
Q2 		$1.28M Sell
23,136
-3,900
-14% -$187K ﹤0.01% 1106
2025
Q1 		$1.31M Hold
27,036
– – ﹤0.01% 1106
2024
Q4 		$1.04M Hold
27,036
– – ﹤0.01% 1296
2024
Q3 		$1.22M Hold
27,036
– – ﹤0.01% 1212
2024
Q2 		$937K Hold
27,036
– – ﹤0.01% 1325
2024
Q1 		$782K Sell
27,036
-1,364
-5% -$37.1K ﹤0.01% 1474
2023
Q4 		$651K Hold
28,400
– – ﹤0.01% 1595
2023
Q3 		$474K Buy
28,400
+12,100
+74% +$235K ﹤0.01% 1607
2023
Q2 		$450K Buy
+16,300
New +$408K ﹤0.01% 1654
2022
Q4 		– Sell
-12,270
Closed -$103K – 2117
2022
Q3 		$103K Buy
12,270
+1,590
+15% +$15K ﹤0.01% 2088
2022
Q2 		$84K Hold
10,680
– – ﹤0.01% 1995
2022
Q1 		$253K Hold
10,680
– – ﹤0.01% 1812
2021
Q4 		$365K Buy
+10,680
New +$338K ﹤0.01% 1743
2021
Q3 		– Sell
-33,230
Closed -$1.49M – 1873
2021
Q2 		$1.49M Hold
33,230
– – ﹤0.01% 1276
2021
Q1 		$861K Hold
33,230
– – ﹤0.01% 1471
2020
Q4 		$670K Sell
33,230
-4,222
-11% -$90.9K ﹤0.01% 1534
2020
Q3 		$732K Buy
+37,452
New +$703K ﹤0.01% 1426

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ensign Peak Advisors's PTGX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Protagonist Therapeutics (PTGX) stake by 16% in Q2 2026, selling an estimated $73.1K and leaving 3,786 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Ensign Peak Advisors first reported a position in PTGX in Q3 2020 and has held it in 21 quarters since. The position peaked at $1.49M in Q2 2021. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Ensign Peak Advisors held 3,786 shares of Protagonist Therapeutics worth $464K as of Q2 2026.
  • Ensign Peak Advisors sold 700 Protagonist Therapeutics shares in Q2 2026, an estimated $73.1K.
  • Protagonist Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1012 holding.
  • Ensign Peak Advisors first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Ensign Peak Advisors's Protagonist Therapeutics position peaked at $1.49M in Q2 2021.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.